NICE not recommending Lutathera for GEP-NETs

The U.K.'s NICE issued draft guidance recommending against the use of Lutathera (177-Lu-Dotatate) from Advanced Accelerator Applications S.A. (NASDAQ:AAAP) to treat gastroenteropancreatic neuroendocrine tumors in adults. In July, CHMP recommended approval of the radiolabeled somatostatin analog that targets somatostatin receptors (see BioCentury Extra, July 21).

According to NICE, the most plausible incremental cost effective ratio (ICER) per quality-adjusted life year (QALY) gained with Lutathera compared to Afinitor everolimus would be greater than the cost-effective range of £20,000-£30,000 ($26,240-$39,360). NICE also said Lutathera did not satisfy criteria to be considered for use in the Cancer Drugs Fund or as a life-extending treatment...